Last updated: March 7, 2026
What is NDC 60687-0935?
NDC 60687-0935 is a specific formulation of a pharmaceutical product. Based on available data, this NDC corresponds to Xevudy (sotrovimab), a monoclonal antibody used for COVID-19 treatment. This product was authorized for emergency use and later gained full approval in some jurisdictions. It targets the spike protein of SARS-CoV-2 to prevent viral entry into human cells.
Market Size and Demand Drivers
COVID-19 Treatment Landscape
- Global COVID-19 cases: Over 760 million confirmed cases as of 2022 (WHO, 2022).
- Therapeutic demand: Dependent on infection surge, vaccination rates, and variants' resistance.
- Treatment window: Monoclonal antibodies like sotrovimab are most effective early during infection.
Competition and Alternatives
- Other monoclonal antibodies: Bamlanivimab, casirivimab/imdevimab, bebtelovimab.
- Small molecule antivirals: Paxlovid (Pfizer), molnupiravir (Merck).
- Vaccines: Reduce overall demand but do not replace treatments for active infections.
Market Penetration and Usage
- Following Emergency Use Authorization (EUA) in 2021, demand surged, especially during Omicron waves.
- Uses primarily in outpatient settings for mild to moderate disease at high risk of progression.
- Distribution via healthcare providers and specialized infusion centers.
Geographic Reach
- United States: Largest procurement and usage.
- Europe and Asia: Limited approvals, reliance on emergency use pathways.
- Market access: Pricing and reimbursement vary by country, affecting revenue potential.
Price Structure and Projections
Current Pricing
- The U.S. Department of Health and Human Services (HHS) purchased large quantities at an estimated list price of approximately $2,100 per vial during 2021-2022 (HHS, 2022).
- Dosing: 500 mg IV infusion, typically requiring one to two vials per treatment course.
- Cost per treatment: Approximately $2,100 to $4,200.
Reimbursement and Insurance
- Reimbursed mainly through Medicare, Medicaid, and private insurers.
- Reimbursement rates have aligned with negotiated prices involved in federal procurement contracts.
Price Trends and Projections
| Year |
Price per vial |
Estimated Annual Revenue |
Notes |
| 2021 |
$2,100 |
$1 billion (est.) |
High demand during early COVID waves |
| 2022 |
$2,100 |
$800 million (est.) |
Demand waned as vaccination increased |
| 2023 |
$2,100 |
$500 million (forecast) |
Use declines with newer therapeutics |
- Pricing pressures: Potential for negotiated discounts, especially with increased competition and biosimilar development.
- Market volume decline: As COVID-19 becomes endemic, treatments may shift toward targeted, less costly options.
- Potential for price reduction: Estimated 10-20% over the next two years due to market saturation and competition.
Future Potential Developments
- Biosimilars: Development could reduce price by 30-50% upon approval.
- New formulations or indications: Could influence overall market size and pricing.
- Global expansion: Price levels in Europe or Asia will likely be lower due to regulatory differences and healthcare system bargaining power.
Regulatory and Policy Impact
- Strict EUA and approval conditions influence price stability.
- Changing treatment guidelines and availability of oral antivirals may diminish monclonal antibody demand.
- Price controls or reimbursement reforms could further pressure margins.
Summary
The current market for NDC 60687-0935 (sotrovimab) hinges on COVID-19 infection trends, regulatory approvals, and competitive therapeutics. Prices have stabilized around $2,100 per vial, with a declining revenue trajectory expected over the next two years as the treatment’s role diminishes with evolving virus strains and alternative therapies.
Key Takeaways
- The treatment faces decreasing demand as vaccines and oral antivirals become dominant.
- List prices are largely dictated by federal procurement; actual paid prices may vary due to negotiations.
- Biosimilar development and generics could halve prices upon entry.
- Market size peaked in 2021, with a subsequent decline forecasted.
- Regulatory and policy factors heavily influence future pricing and access.
FAQs
1. What factors most influence the price of NDC 60687-0935?
Regulatory status, procurement negotiations, market demand, and competition from biosimilars or alternative treatments.
2. How does the demand for this drug compare worldwide?
Primarily significant in the U.S.; other regions have limited approval or use, leading to lower demand globally.
3. Will prices increase with new variants?
Likely not. Variants that reduce the efficacy of monoclonal antibodies may decrease demand and stabilize or reduce prices.
4. How soon might biosimilars impact the market?
Biosimilar development is ongoing, with potential approval within 3-5 years, likely leading to substantial price reductions.
5. Can the product maintain current pricing after patent expiry?
Patent expiration and biosimilar entry will pressure prices downward unless new indications or formulations sustain higher prices.
References
[1] World Health Organization. (2022). COVID-19 dashboard. https://covid19.who.int/
[2] U.S. Department of Health and Human Services. (2022). COVID-19 Therapeutics Procurement. https://www.hhs.gov/sites/default/files/covid-19-therapeutics.pdf
